Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Pre-existing interstitial lung disease in patients with coronavirus disease 2019: A meta-analysis

Lichen Ouyang a,1,*, Jie Gong c,d,1, Muqing Yu b,1

a Department of Immunology, School of Medicine, Jianghan University, Wuhan, China
b Department of Respiratory and Critical Care Medicine, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
c Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
d The Clinical Skill Center, The First Clinical College, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

ARTICLE INFO

Keywords:
COVID-19
Interstitial lung disease

ABSTRACT

Background: The impact of pre-existing interstitial lung disease (ILD) on the severity and mortality of COVID-19 remains largely unknown. The purpose of this meta-analysis was to investigate the prevalence of ILD among patients with COVID-19 and figure out the relationship between ILD and the poor clinical outcomes of COVID-19.

Methods: A systematic literature search was conducted in the PubMed, EMBASE, Web of Science and MedRxiv Database from 1 January 2020 to 26 May 2021.

Results: 15 studies with 135,263 COVID-19 patients were included for analysis of ILD prevalence. The pooled prevalence of comorbid ILD in patients with COVID-19 was 1.4% (95% CI, 1.1%-1.8%, I2 = 91%) with significant between-study heterogeneity. Moreover, the prevalence of ILD in non-survival patients with COVID-19 was 2.728-folds higher than that in corresponding survival patients (RR = 2.728, 95% CI 1.162-6.408, I2 = 54%, p = 0.021). Additionally, 2-3 studies were included for comparison analysis of clinical outcome between COVID-19 patients with and without ILD. The results showed that the mortality of COVID-19 patients with ILD was remarkably elevated compared with patients without ILD (RR = 2.454, 95% CI 1.111-5.421, I2 = 87%, p = 0.026). Meanwhile, the pooled RR of ICU admission for ILD vs. non-ILD cases with COVID-19 was 3.064 (95% CI 1.889-4.972, I2 = 0, p < 0.0001). No significant difference in utilizing rate of mechanical ventilation was observed between COVID-19 patients with and without ILD.

Conclusions: There is great variability in ILD prevalence among patients with COVID-19 across the globe. Pre-existing ILD is associated with higher severity and mortality of COVID-19.

1. Introduction

Coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has posed huge challenges and health/economic burdens worldwide. As of 1 June 2021, more than 170 million confirmed COVID-19 cases including over 3.5 million deaths have been reported worldwide [1]. The clinical manifestation of COVID-19 varies from asymptomatic to severe acute respiratory distress syndrome (ARDS) and even death [2-4]. Identifying vulnerable populations with higher susceptibility and worse outcomes is of great importance for the control and prevention of COVID-19. Currently, elderly males with comorbidities including chronic respiratory diseases, chronic cardiovascular diseases and chronic kidney diseases are at a high risk of experiencing severe COVID-19 and poor prognosis [5,6].

Although several risk factors have been identified to be associated with the severity and mortality of COVID-19, the exact mechanisms underlying disease severity and progression remain unclear. In the current perspective, it is reported that the damage of alveolar (epithelial)-capillary (endothelial) barrier and cytokine storm participate in the pathogenesis and progression of COVID-19 [7-9]. SARS-CoV-2 infection also seems to mount an attack and exacerbate endothelial damage in other vascular beds [8]. Additionally, the inflammatory cytokine cascade induces endothelial activation and capillary leak, leading to circulatory collapse and shock [7,8].

Interstitial lung diseases (ILD) are a heterogeneous group of diseases...
characterized by alveolar damage and interstitial thickening [10,11]. Patients with ILD have poor pulmonary reserve and impaired gas exchange [12]. Furthermore, ILD patients with viral infection can trigger acute exacerbations which are related to their poor prognosis [13]. Importantly, the functional impairment and injury of lung endothelial cells have been reported to contribute to the development and progression of ILD [14,15]. Thus, it is reasonable to speculate that ILD increases susceptibility and severity of COVID-19. This was supported by several studies from South Korea and the UK reporting the risk of COVID-19, severity and mortality were higher in patients with ILD compared with those without [16,17]. However, a study from Belgium demonstrated no increased occurrence of severe COVID-19 in ILD patients compared to the general population [18]. In view of the above-mentioned studies, the relationship between ILD and COVID-19 remains controversial. A meta-analysis with large clinical samples is warranted to draw a reliable conclusion.

In this study, we performed a systematic review and quantitative meta-analysis to report the prevalence of ILD among patients with COVID-19 and investigate the relationship between pre-existing ILD and poor outcomes of COVID-19.

2. Methods

This systematic review and meta-analysis were performed according to the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions and reported based on Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines [19].

2.1. Search strategy

Articles published from 1 January 2020 to 26 May 2021 in Pubmed, EMBASE, Web of Science and MedRxiv Database were searched. To identify all the articles regarding the prevalence of ILD in COVID-19 and relationship between ILD and COVID-19, we used the following terms alone or in combination for literature search: “SARS-CoV-2”, “COVID-19”, “2019-nCoV”, “nCoV”, “coronavirus”, “severe acute respiratory syndrome coronavirus 2”, “interstitial lung disease”, “ILD” and “interstitial pneumonia”.

2.2. Inclusion and exclusion criteria

Studies were included if they met the following criteria: (1) Subjects: adult patients diagnosed with COVID-19 according to the guidelines for the diagnosis and treatment of novel coronavirus disease; (2) Outcomes: the number of ILD patients among COVID-19 patients; or comparison data of ILD prevalence between survival and non-survival COVID-19 patients; or comparison data of COVID-19 outcome (mortality and severity) between patients with ILD and those without.

Exclusion criteria included: (1) studies with special populations, such as children, elderly, pregnant women; (2) case reports, reviews, meta-analysis, guidelines, editorials and comments; (3) sample size is less than 20 patients; (4) publications with overlapping data and studies in non-English languages. The flowchart of the study selection has been drafted in accordance with the PRISMA principle.

2.3. Data extraction and quality assessment

Two investigators worked independently to decide which studies should be included, and conflicts were resolved by a third investigator. Data was extracted from selected studies including the first author, publication date, country, sex, mean age, number of COVID-19 patients, and study type. In addition, data regarding the number of ILD patients among COVID-19 patients, comparison data of ILD prevalence between survival and non-survival COVID-19 patients, or comparison data of COVID-19 outcome (mortality and severity) between patients with and
without ILD were also extracted. The data shown as median and interquartile range was transformed into mean and standard deviation (SD) according to the formula below (http://www.math.hkbu.edu.hk/~tongt/papers/median2mean.html). The prevalence of ILD was compared between survival and non-survival groups. The mortality and severity of COVID-19 were evaluated between ILD and non-ILD groups.

The quality of included studies was evaluated according to the Newcastle-Ottawa scale (NOS) containing three aspects (selection, comparability and outcome) [20]. Scores range from 0 to 9, and the quality of the studies was regarded as low (0–3), moderate (4–6), or high (7–9), respectively.

2.4. Statistical analysis

All statistical analyses were performed using the “meta” package in R software (version 4.0.2) [21]. The “metaprop” command in R was performed to calculate the pooled prevalence estimates of ILD with 95% confidence in patients with COVID-19. The “metabin” function was used to calculate the risk ratio (RR) of comorbid ILD between survival and non-survival COVID-19 patients. The RR of COVID-19 outcomes formation to calculate the pooled prevalence estimates of ILD with 95% confidence in patients with COVID-19. The prevalence of ILD was calculated to combine the data. The magnitude of heterogeneity between different studies was tested using I² statistic. Subgroup analysis and meta-regression based on geographical location, sample size, study type and quality score were performed to explore the origin of heterogeneity. Publication bias was evaluated by funnel plot and Egger test if the number of included studies > 10 [22]. P value < 0.05 was regarded as statistically significant.

3. Results

3.1. Study selection

A total of 2693 articles were retrieved according to our search strategy. Firstly, duplicate articles (n = 982) were excluded. After reviewing the titles and abstracts, 1578 articles were ruled out. The 133 remaining articles were full-text reviewed for eligibility. 116 articles were excluded due to the following reasons: studies focused on special populations (n = 25); studies without available data (n = 89), studies with overlapped data (n = 2). Finally, 17 articles with 14,094 patients were included in our meta-analysis. Fig. 1 showed the flow diagram of the study selection.

| Study            | Country   | Center     | Type of study     | Sample size, n | Male N. (%) | Age (mean) | Population | ILD prevalence (%) |
|------------------|-----------|------------|-------------------|----------------|-------------|------------|-------------|--------------------|
| Aveyard P [16]   | UK        | Multicenter| retrospective cohort | 14,479        | 8038(55.5%) | 69.9       | Community  | 2                  |
| Drake TM [31]    | UK        | Multicenter| retrospective case-control | 483          | 330(68.3%)  | 73.2       | Hospital   | /                  |
| Argenziano MG [32] | USA     | Multicenter| retrospective case series | 1000         | 596(59.6%)  | 62.6       | Hospital   | 1.3                |
| Beltramo G [33]  | France    | Multicenter| retrospective cohort  | 89,530        | 47,495      | 65         | Hospital   | 1.8                |
| Huang H [34]     | China     | Single center | retrospective cross-section | 3201         | /           | /          | Hospital   | 0.9                |
| Brenner DS [35]  | USA       | Multicenter| retrospective cohort  | 93            | 52(56%)     | 54.2       | Hospital   | 1.1                |
| Sapye E [36]     | UK        | Single center | retrospective cross-section | 2217            | 1200(58.2%)  | 71.6       | Hospital   | 2.2                |
| Hussain M [37]   | Pakistan  | Single center | retrospective cross-section | 212          | 120(56.6%)  | 52         | Community  | 6.6                |
| Eman M [38]      | Egypt     | Multicenter| retrospective cohort  | 439           | 224(51%)    | 51.2       | Hospital   | 0.7                |
| Espósito AJ [39] | USA       | Multicenter| retrospective case-control | 138          | 48 (35%)    | /          | Hospital   | /                  |
| Lee H [17]       | South Korea | Multicenter | retrospective case-control | 8070            | 3236 (40.1%) | /          | Nationwide  | 0.8                |
| Morgenathaus AS [40] | USA    | Multicenter| retrospective cohort  | 7337          | 4061(55.3%) | /          | Hospital   | 0.5                |
| Signes-Costa J [41] | Spain | Multicenter| retrospective cohort  | 5847          | 3432(58.7%) | 65.1       | Hospital   | 1.8                |
| Awano N [42]     | Japan     | Single center | retrospective cohort  | 54            | 38(70.4%)   | 48.8       | Hospital   | 3.7                |
| Kokturk N [43]   | Turkey    | Multicenter| retrospective cohort  | 1500          | 850(57%)    | 51.88      | Nationwide  | 1.5                |
| Riou M [44]      | France    | Single center | retrospective cohort  | 124            | 75(60%)    | 62.7       | Hospital   | 2.4                |
| Memel ZN [45]    | USA       | Single center | retrospective cohort  | 1179          | 676 (57.3%) | /          | Hospital   | 0.8                |

Table 2: Quality assessment of included studies by Newcastle-Ottawa scale (NOS).

| Study            | Newcastle Ottawa Scale score | Total (1/9) | Quality |
|------------------|-----------------------------|-------------|---------|
| Aveyard P        | 4                            | 2           | 2       | 8       | High   |
| Drake TM         | 3                            | 2           | 2       | 7       | High   |
| Argenziano MG    | 4                            | 1           | 2       | 7       | High   |
| Beltramo G       | 3                            | 2           | 2       | 7       | High   |
| Huang N          | 4                            | 0           | 1       | 5       | Moderate |
| Brenner DS       | 2                            | 2           | 2       | 6       | Moderate |
| Sapye E          | 4                            | 2           | 2       | 8       | High   |
| Hussain M        | 3                            | 0           | 0       | 3       | Low    |
| Eman M           | 4                            | 2           | 2       | 8       | High   |
| Espósito AJ      | 4                            | 2           | 2       | 8       | High   |
| Lee H            | 4                            | 2           | 2       | 8       | High   |
| Morgenathaus AS  | 4                            | 2           | 2       | 8       | High   |
| Signes-Costa J   | 4                            | 2           | 2       | 8       | High   |
| Awano N          | 3                            | 2           | 1       | 6       | Moderate |
| Kokturk N        | 4                            | 2           | 1       | 7       | High   |
| Riou M           | 3                            | 2           | 2       | 7       | High   |
| Memel ZN         | 4                            | 2           | 2       | 8       | High   |

3.2. Study characteristics

The main characteristics of the included studies are shown in Table 1. Most of the included studies were retrospective cohort studies. 11 studies were conducted in multicenter and 6 studies in single-center. The studies were from various countries across the globe, of which 6 were from Europe, 5 from Americas, 5 from Asia, and 1 from Africa. The quality of the studies was evaluated using the Newcastle-Ottawa scale. As shown in Table 2, 13 studies were of high quality, 3 studies of moderate quality, and the remaining 1 study of low quality.

3.3. The pooled prevalence of ILD in COVID-19 patients

Among 17 studies, 15 studies from 10 countries with 135263 COVID-19 patients reported prevalence of ILD. The pooled prevalence of comorbid ILD in patients with COVID-19 was 1.4% (95% CI, 1.1%-1.8%, I² = 91%), random-effects model: Fig. 2). Considering the significant between-study heterogeneity, we performed subgroup analysis and meta-regression to explore the possible factors based on geographical location, sample size, study type and quality score (Table 3, supplemental Figs. 1–4). Subgroup analysis based on geographical location
showed that the pooled prevalence of ILD in COVID-19 patients was 1.8% (95% CI 1.8%-1.9%, \( I^2 = 0 \)) in Europe, 0.8% (95% CI 0.5%-1.4%, \( I^2 = 67\% \)) in the Americas, 1.8% (95% CI 0.9%-3.6%, \( I^2 = 93\% \)) in Asia, respectively. Only 1 study was from Africa, and the prevalence of ILD in patients with COVID-19 was 0.7% (95% CI, 0.2%-2.1%). Univariate meta-regression demonstrated that geographical location (\( P = 0.0009 \)), sample size (\( P = 0.0069 \)), quality score (\( P = 0.0008 \)) might be factors leading to heterogeneity, whereas no significant differences were found in study type (\( P = 0.171 \)).

### 3.4. The association of poor outcomes of COVID-19 patients with ILD

To figure out the association of ILD and clinical outcome of patients with COVID-19, we compared the estimated prevalence of ILD between survival and non-survival patients with COVID-19. As shown in Fig. 3, only two studies were included and combined. The prevalence of ILD was significantly higher in the non-survival group compared to the survival group (RR = 2.728, 95% CI 1.162-6.408, \( I^2 = 54\% \), \( p = 0.021 \); Fig. 3A). Furthermore, we also compared clinical outcomes of COVID-19 between patients with and without ILD. The mortality rate was significantly higher in patients with ILD than those without (RR = 2.454, 95% CI 1.111-5.421, \( I^2 = 87\% \), \( p = 0.026 \); Fig. 3B). Considering the significant between-study heterogeneity, we performed subgroup analysis to explore the origin of heterogeneity. As shown in Fig. 3 and Table 1, the sex ratio difference of cohort in studies may contribute partly to the heterogeneity. In addition, the rate of ICU admission was higher in patients with ILD than those without (RR = 3.064, 95% CI 1.889-4.972, \( I^2 = 0 \), \( p < 0.0001 \); Fig. 3D). However, no significant difference in utilizing rate of mechanical ventilation was observed between patients with and without ILD (RR = 1.863, 95% CI 0.362-9.582, \( I^2 = 93\% \), \( p = 0.456 \); Fig. 3C).

#### 3.5. Publication bias

No significant publication bias was found by funnel plot and Egger test (\( P = 0.274 \)).

### 4. Discussion

To our knowledge, this meta-analysis is the first to report the pooled estimated prevalence of ILD in patients with COVID-19 as well as the relationship between ILD and COVID-19 based on a large COVID-19 population. Our results showed that the prevalence of ILD in COVID-19 patients across the globe was 1.4% with significant between-study heterogeneity. The following subgroup analysis and meta-regression demonstrated that geographical location, sample size and quality score might be potential sources of heterogeneity. The ILD prevalence was significantly higher in non-survival COVID-19 patients compared to their survival counterparts. In addition, a higher risk of death and ICU admission was found in COVID-19 patients with ILD compared to those without. Taken together, our results suggest that ILD is associated with poor outcomes of COVID-19.

ILD refers to a large, heterogeneous group of more than 300 different entities with known or unknown etiology, most of which are classified as non-common diseases [23]. Among the ILDs, the most common is sarcoidosis, while idiopathic pulmonary fibrosis (IPF) is the most severe [23]. Other major ILDs consisted of hypersensitivity pneumonitis (HP), also called extrinsic allergic alveolitis (EAA), connective tissue disease associated ILD (CTD-ILD), and drug-induced ILD (DILD) [24]. It is reported that the prevalence estimates of ILD with fibrosis ranges from 42.7 to 63 per 100.000 population in the USA and 1.25–23.4 per 100.000 population in Europe [25]. Our results revealed that the pooled prevalence of ILD in...
COVID-19 patients was 1.8% in Europe and 0.8% in the Americas, which is higher than the reported prevalence of ILD in the general population. A possible reason is that ILD patients, especially IPF patients, tend to be older and have multiple comorbidities which is suggested to increase the risk of COVID-19 [26]. These evidence indicate that ILD patients are susceptible to COVID-19.

In our study, we found that the prevalence of ILD was significantly higher in non-survival groups than that in survival groups. Furthermore, the risk of death and ICU admission in COVID-19 patients was higher in patients with ILD compared to those without. These results suggest that ILD might be a risk factor for poor clinical outcomes of patients with COVID-19. The reasons underlying it are complicated and possibly multifactorial. Firstly, it is suggested that ILD renders the host susceptible to respiratory viral infection which is recognized as the main trigger for exacerbations of ILD and related with severe adverse outcomes [27], although the exact mechanism underlying the event is unknown. Given the impaired lung reserve and gas exchange of ILD patients, the SARS-COV-2 infection of ILD patients could be the proverbial straw that breaks the camel’s back. ILD patients with SARS-COV-2 infection may be more likely to develop severe ARDS, respiratory failure, or even death. Secondly, ILD patients, especially patients with CTD-ILD are often treated with corticosteroids and/or immunosuppressive agents [28]. Although the robust data regarding the impact of corticosteroids/immunosuppressive agents on severity and mortality of COVID-19 are still lacking, previous data have suggested that ILD patients receiving immunomodulatory agents have an increased risk of viral infections such as influenza, rhino- and adenovirus [29]. Corticosteroid treatment is also suggested to lead to increased viremia, delayed clearance of viral, and an increased length of hospital stay in studies of coronavirus infections [30]. Therefore, it could be another explanation...
of poor outcomes in ILD patients.

To the best of our knowledge, this meta-analysis is the first to evaluate the relationship between ILD and COVID-19 outcome (mortality and severity). Pre-existing ILD is a risk factor influencing the progression and prognosis of COVID-19. However, this study is descriptive and the underlying mechanisms behind the results are poorly understood. Further research is needed to investigate the effect of the endothelial dysfunction associated with ILD on the cytokine storm caused by SARS-CoV-2. Several limitations inevitably exist in our meta-analysis. First, due to the lack of data.

ILD is associated with a higher risk of poor clinical outcomes in patients with COVID-19. Therefore, it is necessary for respiratory doctors to pay more attention to COVID-19 patients with pre-existing ILD and implement optimized interventions and treatments for them during a COVID-19 epidemic.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author contributions

Lichen Ouyang designed the search strategy, screened studies for eligibility, conducted the data analysis, and wrote the first draft of the manuscript. Muqing Yu conceived the study, screened studies for eligibility, and critically revised the manuscript. Jie Gong addressed disputes in the manuscript. All co-authors were involved in editing of the manuscript and critically revised the manuscript. L. Ouyang et al.

References

[1] W.H. Organization, WHO coronavirus (COVID-19) dashboard, 2021.

[2] T. Singhai, A review of coronavirus disease-2019 (COVID-19), Indian J. Pediatr. 87 (4) (2020) 281–286.

[3] P. Gori, F. Salton, L. Zuccato, M. Tamburini, M. Biolo, A. Bunca, M. Santagiuliana, U. Zaccou, P. Confalonieri, B. Ruaoro, P. D’Agaro, S. Gasparini, M. Confalonieri, Limited role for bronchoalveolar lavage to exclude COVID-19 after negative upper respiratory trawal: a multicentre study. Eur. Respir. J. 56 (4) (2020).

[4] F. Salton, P. Confalonieri, G.U. Meduri, P. Santus, S. Harari, R. Scala, S. Lanini, V. Vertui, T. Ogigioni, A. Caminati, V. Patruno, M. Tamburrini, A. Scarthabelli, M. Parati, M. Villani, D. Radovandovic, S. Tomassetti, C. Ravaglia, V. Poletti, A. Viansato, A.T. Gaccheone, L. Guidelli, R. Rancanelli, P. Lucornelli, D. Lacandona, M.P. Foschino Barbaro, S. Centenni, M. Mondoni, M. Davi, A. Fanti, X. Cao, L. Torelli, A. Zucchetto, M. Montico, A. Casarin, M. Romagnoli, S. Gasparini, M. Bonifazi, P. D’Agaro, A. Marcello, D. Licantoni, B. Ruaro, M.C. Volpe, R. Urmberger, M. Confalonieri, Prolonged low-dose methylprednisolone in patients with severe COVID-19 Pneu, Open Forum Infect Dis 7 (10) (2020) eoa21.

[5] W.-J. Guan, W.-H. Liang, Y.-J. Zhao, K.-H. Liang, Z.-Z. Chen, Y.-M. Li, X.-Q. Liu, R.-C. Chen, C.-L. Tang, W. Wang, C.-P. Ou, L. Li, P.-Y. Wang, W. Wang, S.-H. Li, J.-S. Li, C.-C. Li, L.-M. Ou, B.O. Cheng, S. Xiong, Z.-Y. Ji, X. Jiang, Y. Hu, L. Liu, H. Shan, C.-L. Lei, Y.X. Peng, L. Wei, Y. Liu, Y.-H. Hu, P. Peng, M.J. Wang, J.Y. Liu, Z. Chen, G. Li, Z.-J. Zheng, S.-Q. Qiu, J. Luo, C.-J. Ye, S.-Y. Zhu, L.-H. Cheng, F. Ye, S.-Y. Li, J.-P. Zheng, N.-F. Zhang, N.-S. Zhong, J.-X. He, China medical treatment expert group for, comorbidities and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur. Respirat. J. 55 (5) (2020).

[6] K. Dorjee, H. Kim, E. Bonomo, R. Dolma, B. Bolgnano, Prevalence and predictors of death and severe disease in patients hospitalized due to COVID-19: a comprehensive systematic review and meta-analysis of 77 studies and 38,000 patients, PLoS ONE 15 (12) (2020) e0243191.

[7] L. Pearce, S.M. Davidson, D.M. Yellon, The cytokine storm of COVID-19: a spotlight on prevention and protection, Expert Opin Ther Targets 24 (8) (2020) 723–730.

[8] S. Kaur, D.M. Tripathi, A. Yadav, The Enigma of Endothelium in Coronavirus, J. Physiol. 911 (2021).

[9] A. Matarase, J. Gambardella, C. Sardo, G. Sastelli, miR-98 regulates TMRPSS2 expression in human endothelial cells; key implications for COVID-19, Biomedecines (8) (10) (2020) 462, https://doi.org/10.3390/biomedicines8110462.

[10] O.R. Kalichm-Dekel, J. Galvin, A. Burke, S. Atamas, N. Todd, Interstitial lung disease and pulmonary fibrosis: a practical approach for general medicine physicians with focus on the medical history, J. Clin. Med. 7 (12) (2018) 476, https://doi.org/10.3390/jcm7120476.

[11] E. Baratella, B. Ruofo, F. Giudici, B. Wade, M. Santagiuliana, F. Salton, P. Confalonieri, M. Simbolino, A. Scarpa, S. Toliott, C. Marroccio, M.A. Costa, V. Confalonieri, Evaluation of Correlations between Genetic Variants and High-Resolution Computed Tomography Patterns in Idiopathic Pulmonary Fibrosis, Diagnostics (Basel, Switzerland) 11 (5) (2021).

[12] A.J. Podolanczuk, L. Richeldi, COVID-19 and interstitial lung disease: keep them apart, Am. J. Respir. Crit. Care Med. 202 (12) (2020) 1614–1616.

[13] N. Azadeh, A.H. Limper, E.M. Carmona, J.H. Ryu, The role of infection in interstitial lung diseases: a review, Chest 152 (4) (2017) 842–852.

[14] S. Kato, N. Inui, A. Hakamata, Y. Suzuki, N. Enomoto, T. Fujisawa, Y. Nakamura, H. Watanabe, T. Suda, Changes in pulmonary endothelial cell properties during bleomycin-induced pulmonary fibrosis, Respir. Res. 19 (1) (2018) 127.

[15] P.V. Castellino, J. Varga, Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management, Arthritis Res Ther 12 (4) (2010) 213, https://doi.org/10.1186/ar309.

[16] P. Aveyard, M. Gao, N. Lindson, J. Hartmey-Buycke, P. Watkinsong, D. Young, C.A. C. Coupland, P.S. Tan, A.K. Clift, D. Harrison, D.W. Gould, I.D. Favour, J. Hippisley-Cox, Associations between pre-existing respiratory conditions and their treatment, and severe COVID-19: a population cohort study, The Lancet Respiratory medicine (2021).

[17] H. Lee, H. Choi, B. Yang, S.-K. Lee, T.S. Park, D.W. Park, J.Y. Moon, T.-H. Kim, W.-R. J. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Yoon, S.A. Hye, J.L. Y.
[26] Charlotte Hyldgaard, Ole Hilberg, Elisabeth Bendstrup, How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respir. Med. 108 (4) (2014) 647–653.
[27] Mario Fonseca, Ross Summer, Jesse Roman, Acute Exacerbation of interstitial lung disease as a sequel of COVID-19 pneumonia, Am. J. Med. Sci. 361 (1) (2021) 126–129.
[28] B. Wallace, D. Vummidi, D. Khanna, Management of connective tissue diseases associated interstitial lung disease: a review of the published literature, Curr. Opin. Rheumatol. 28 (3) (2016) 236–245.
[29] C.J. Britto, V. Brady, S. Lee, C.S. Dela Cruz, Respiratory Viral Infections in Chronic Lung Diseases, Clin Chest Med 38(1) (2017) 87-96.
[30] Y.M. Arabi, Y. Mandourah, F. Al-Hameed, A.A. Sindi, G.A. Almekhlafi, M.A. Alraddadi, S. Shalhoub, A. Abdulmomen, I. Qushmaq, A. Mady, O. Solaiman, A.M. K. Hashem, Impact of comorbidities on COVID-19 outcome, medRxiv (2020).
[31] A.J. Esposito, A.A. Menon, A.J. Ghost, R.K. Putman, L.E. Fordenburgh, S.Y. El-Chehly, J.H. Goldberg, R.M. Baron, G.M. Hummingle, T.J. Doyle, Increased odds of death for patients with interstitial lung disease and COVID-19: a Case-control study, Am. J. Respir. Crit. Care Med. 202 (12) (2020) 1710–1713.
[32] Adam S. Morgenthau, Matthew A. Levin, Robert Freeman, David L. Reich, Eyal Klanger, Moderate or severe impairment in pulmonary function is associated with mortality in sarcoidosis patients infected with SARS-CoV2, Lung 198 (5) (2020) 771–775.
[33] J. Signes-Costa, I.N. Nunez-Gil, J.B. Soriano, R. Romero, A. Uribarri, I. Fernandez-Rozas, M.G. Aguado, V.M. Becerra-Munoz, J. Hurley, M. Jones, M. Kokosi, M. Kreuter, L.S. MacKay, S. Mahendran, M. Molyneaux, A. Ozturk, O. P. Margaritopoulos, M. Molina-Molina, P.L. Molyneaux, A. O’Brien, K. O’Reilly, A. Packham, H. Panredy, V. Poletti, J.C. Porter, E. Renzoni, P. Rivera-Ortega, A. Takehiro Izumo, Serum KL-6 level is a useful biomarker for evaluating the severity of coronavirus disease 2019, Respirat. Investigat. 58 (6) (2020) 440–447.
[34] N. Kokturk, C. Babayigit, S. Kli, P. Duru, H. Sarslan, A. Arslan Baris, O. Kaygısız, O. Karcioglu, P. Aysert, I. Mirak, A. Akbas, C. Gokgoz, L. Ergan, V. Avkan Oguz, O. Baydar Toprak, Takehiro Izumo, Serum KL-6 level is a useful biomarker for evaluating the severity of coronavirus disease 2019, Respirat. Investigat. 58 (6) (2020) 440–447.
[35] N. Kokturk, C. Babayigit, S. Kli, P. Duru, H. Sarslan, A. Arslan Baris, O. Kaygısız, O. Karcioglu, P. Aysert, I. Mirak, A. Akbas, C. Gokgoz, L. Ergan, V. Avkan Oguz, O. Baydar Toprak, Takehiro Izumo, Serum KL-6 level is a useful biomarker for evaluating the severity of coronavirus disease 2019, Respirat. Investigat. 58 (6) (2020) 440–447.
[36] E. Sapey, S. Gallier, C. Mainey, P. Nightingale, D. McNulty, H. Crothers, E. Evison, K. Reeves, D. Pagano, A.K. Denmiston, K. Nirantharukumar, P. Diggle, S. Ball, Ethnicity and risk of death in patients hospitalised for COVID-19 infection in the UK: An observational cohort study in an urban catchment area, BMJ open respiratory research 7 (1) (no pagination)(2020).
[37] M. Hussain, S. Ihlaf Sr., S. Salman, S. Abbas, M. Fatima, Frequency of comorbidities in admitting COVID-19 pneumonia patients in a tertiary care setup: an observational study, Cures 13 (2) (2021), e13546.
[38] E.M. Khedr, E. Daef, A. Mohamed-Hussein, E.F. Mostafa, M. Zein, S.M. Hassany, H. Galal, S.A. Hassan, I. Galal, A.A. Zaraour, H.F. Hetta, H.M. Hassan, M.T. Amin, M. K. Hashem, Impact of comorbidities on COVID-19 outcome, medRxiv (2020).
[39] A.I. Stewart, R.G. Jenkins, I.C. Investigators, Outcome of hospitalization for COVID-19 in patients with interstitial lung disease an international multicenter study, Am. J. Respir. Crit. Care Med. 202 (12) (2020) 1656–1665.